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ABSTRACT Legius syndrome (LS) is an autosomal dominant disorder caused by germline loss-of-function
mutations in the sprouty-related, EVH1 domain containing 1 (SPRED1) gene. The phenotype of LS is
multiple café au lait macules (CALM) with other commonly reported manifestations, including intertriginous
freckling, lipomas, macrocephaly, and learning disabilities including ADHD and developmental delays.
Since the earliest signs of LS and neuroﬁbromatosis type 1 (NF1) syndrome are pigmentary ﬁndings, the
two are indistinguishable and individuals with LS may meet the National Institutes of Health diagnostic
criteria for NF1 syndrome. However, individuals are not known to have an increased risk for developing
tumors (compared with NF1 patients). It is therefore important to fully characterize the phenotype differ-
ences between NF1 and LS because the prognoses of these two disorders differ greatly. We have de-
veloped a mutation database that characterizes the known variants in the SPRED1 gene in an effort to
facilitate this process for testing and interpreting results. This database is free to the public and will be
updated quarterly.
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Legius syndrome (LS; MIM #611431) is an inherited disease caused by
autosomal dominant loss-of-function (LOF) mutations in the sprouty-
related, EVH1 domain containing 1 (SPRED1) gene (MIM #609291)
(Brems et al. 2007). LS, also known as neuroﬁbromatosis type 1 (NF1)-
like syndrome, is a disorder with a pigmentary phenotype overlapping
with NF1 syndrome. Individuals with LS may meet the diagnostic
criteria set by the National Institutes of Health (NIH) for NF1
syndrome (Brems, et al., 2007; Pasmant, et al., 2009; Stevenson,
et al. 2010), except people with LS have not been shown to develop
tumors as found in NF1(Muram-Zborovski et al. 2010). Additional
manifestations associated with LS have also been reported in indi-
viduals with NF1 (i.e., macrocephaly, lipomas, learning difﬁculties,
Noonan syndrome-like facial features, attention deﬁcit and hyperac-
tivity disorder (ADHD), and pectus excavatum (Brems et al. 2007;
Friedman 1998; Muram-Zborovski et al. 2010; Pasmant et al. 2009).
For a clinical diagnosis of NF1, an individual must meet two or more
of the following criteria: six or more café-au-lait macules (CALM);
two or more neuroﬁbromas or one plexiform neuroﬁbroma; freck-
ling in the axillary or inguinal regions; optic glioma; two or more
Lisch nodules; distinctive osseous lesion; and/or a ﬁrst-degree rela-
tive with the diagnosis of NF1. LS patients may meet the NIH di-
agnostic criteria for NF1 based on pigmentary ﬁndings of café-au-
lait macules and distinctive freckling pattern alone. It is therefore
important to fully characterize the phenotype differences between LS
and NF1 because the prognoses for these two disorders differ sig-
niﬁcantly. This is especially true in children, as deﬁnitive features of
NF1 are acquired with age, and the only manifestation may be
CALM and axillary/inguinal freckling, making it difﬁcult to differ-
entiate between LS and NF1 without genetic testing.
The SPRED1 gene, located on chromosomal region 15q3.2, con-
tains seven coding exons and produces a protein that is a negative
regulator of the RAS-MAPK signaling pathway. It is believed that
SPRED1 interacts directly with RAS-RAF signaling and that most
germline mutations in the SPRED1 gene result in a truncated protein
that is incapable of properly interacting with the RAS pathway.
However, pathogenic missense mutations, as well as large deletions
encompassing part of or the entire SPRED1 gene, have been described,
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resulting in protein products unable to properly regulate the RAS-
MAPK pathway. These mutations can produce a LS phenotype and
may complicate the interpretation of genetic testing results. As such,
clinical and research laboratories that offer SPRED1 gene analysis
often encounter rare variations and must rely on the published liter-
ature or online resources to determine the clinical relevance of the
identiﬁed variant. We have developed a database devoted to LS-related
mutations in the SPRED1 gene to facilitate this process.
We have recently reported gene variant archives for galactosemia
(GALT), multiple endocrine neoplasia type 2 (RET), juvenile polyposis
syndrome (SMAD4), and X-linked Alport syndrome (COL4A5). These
clinically curated archives uniquely display genotype and associated
phenotype information. Here, we introduce a new disease database for
LS syndrome and SPRED1 gene variants. This database was developed
to serve as a reference for all sequence variations currently reported in
the SPRED1 gene as well as to provide as much phenotype informa-
tion as possible (Calderon et al. 2007; Crockett et al. 2010; Margraf
et al. 2009; Wooderchak et al. 2010). To date, 78 variants have been
described in the SPRED1 gene, of which 49 have been classiﬁed as
disease causing or pathogenic, 1 as suspected pathogenic, 7 as sus-
pected benign, 8 as benign polymorphisms, and 13 with uncertain
signiﬁcance (Brems et al. 2007; Denayer et al. 2011; Messiaen et al.
2009; Muram-Zborovski et al. 2010; Pasmant et al. 2009; Spencer et al.
2011; Spurlock et al. 2009).
SPRED1 variant database objectives
The aim of the SPRED1 variant database is to record all known
variants in the SPRED1 gene and their associated phenotype. This
database is freely available to the public, and users are encouraged
to submit newly discovered variants to the database curator using the
“Database Submission” webpage. This form also can be used to update
clinical information or to clarify the classiﬁcation or phenotype for
existing sequence variants. The submission form requests information
on the sequence variation, clinical consequences, publications, and the
submitter’s contact information. Those submitting new variants to the
database are expected to follow their own Institutional Review Board
protocols or consenting processes, as their host institutions deem
necessary. To maintain the accuracy and utility of the SPRED1 data-
base, content will be updated quarterly using new sequence variation
information from literature reports, database submissions and
updates, and routine clinical testing performed at ARUP Laboratories.
The original start date and date of the latest update is displayed on the
SPRED1 “Home” webpage.
METHODS
Data sources and limitations
The SPRED1 database was constructed using gene sequence variation
data published in the scientiﬁc literature since the SPRED1 gene was
ﬁrst identiﬁed in patients with a NF1-like phenotype but with no
identiﬁable NF1 gene mutation in 2007 (Brems et al. 2007). To date,
78 sequence variants have been found by searching PubMed (http://
www.ncbi.nlm.nih.gov/sites/entrez) and Google (http://google.com/).
Search terms included SPRED1, Legius syndrome,a n dNF1-like syn-
drome. Occasionally, laboratory-sequencing results that identify novel
gene variants are also included in this archive. The database was
constructed using the Human Genome Variation Society (HGVS)
and Human Genome Organization (HUGO) Mutation Database Ini-
tiative recommendations for essential and optional content (http://
www.hgvs.org/mdifaq.html). HGVS nomenclature recommendations
for description of sequence variants were used to generate DNA and
protein changes for this database. Reference sequences for this data-
base were GenBank NC_000015.9, NM_1525940.2, and NP_689807.1;
entries were veriﬁed for position and name based on these sequences.
All sequence variants in the database (including future updates) are
named based on their position in relation to the coding regions of the
SPRED1 gene (cDNA) following recommendations listed by the
HGVS (http://www.hgvs.org/mutnomen) and described in Den Dunnen
and Antonarakis (2000). To comply with sequence variant nomen-
clature according to the guidelines of the Human Genome Variation
Society, the online batch position check tool Mutalyzer 2.0 (http://
www.mutalyzer.nl/) was used to conﬁrm genomic position of all
SPRED1 gene variants (Wildeman et al. 2008).
Software
SQL tables (MySQL, Inc.) were organized to represent SPRED1 mu-
tation status, associated phenotype, literature references, and any
known clinical information. PHP coding was performed in-house
for dynamic HTML display to render pages and display SQL tables.
Graphics were generated using FusionCharts v3 (www.fusioncharts.
com). Web pages are hosted on a Mac OS X Apache server. SPRED1
mutations were added to the database and edited using phpmyadmin
(www.phpmyadmin.net).
RESULTS AND DISCUSSION
SPRED1 database website
The SPRED1 database can be found under Disease Databases on the
ARUP Online Scientiﬁc Resource webpage http://www.arup.utah.edu/
or accessed directly by using the URL http://www.arup.utah.edu/
database/SPRED1/SPRED1_welcome.php. Navigation between the se-
ries of webpages can be done using the quick links as shown in Figure
1A. The SPRED1 “Home” webpage brieﬂy describes Legius syndrome,
phenotype, the database goals, reference sequences used, and gene
sequencing tests available at ARUP Laboratories. The right frame of
the page conveniently lists contact information for the appropriate
experts involved in the database development and curation, including
medical director, submissions, testing, and website administrator. The
“Home” page also provides a graphic link to the SPRED1 gene topic
hosted by the National Library of Medicine’s Genetics Home Refer-
ence (http://ghr.nlm.nih.gov/gene/SPRED1).
The SPRED1 “Links” webpage has hyperlinks to existing online
resources for Legius syndrome and SPRED1, including Databases,
Gene and Protein Links, Web Reviews, and Literature Reviews. Some
of the resources listed here include Gene Reviews, Genetics Home
Reference, OMIM, UniProt, Human Protein Reference Database
(HPRD), and the SPRED1 reference sequences used for our database
curation. Lastly, recent literature reviews from experts in this disease
area are posted and updated as appropriate.
The SPRED1 database can be displayed and searched in its en-
tirety by accessing the “Database” webpage shown in Figure 1B. The
database contained 78 entries as of May 2011. The default database
display is by genomic position of each sequence variant (59 to 39)
within the SPRED1 gene. Figure 1C shows the database display
columns of Location, Mutation Type, Nucleotide Change, Protein
Change, Classiﬁcation, Meets NIH NF1 Criteria, References, and
Comments. Information in the Comments column (Figure 1D) is
available by placing the pointer over the comments icon. This
information may further explain the data displayed for each entry.
The database also has “live search” functionality, so that any term
entered in the search box (e.g., exon, insertion, benign, or author
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any column heading will sort (ascending and descending) the gene
variant entries for redisplay.
The “Submissions” webpage is used for submission of novel
SPRED1 sequence variants to the database or to update information
for sequence variations currently archived in the database. Contact
i n f o r m a t i o ni sc o n v e n i e n t l ys e e no nt h e“Home” and “Links” pages.
Requested information during submission includes gene variant loca-
tion, mutation type, classiﬁcation, nucleotide change, protein change,
clinical signiﬁcance, and contact information of the submitter. All
Figure 1 Legius syndrome database display. (A) Quick links for navigation within the website for SPRED1 homepage, database display, links, and
submission. (B) Main database display including a “live search” function for easy ﬁltering to gene variants of interest. (C) Clicking any display
column heading will sort gene variants in ascending or descending order. (D) Mouse-over function for additional clinical “Comments” column
follows the literature reference column.
Volume 1 November 2011 | SPRED1 Variants Repository | 453submissions are received via autogenerated e-mail to the curators, and
variant updates are added to the database quarterly.
Database display columns
SPRED1 sequence variation location and mutation type: The
Location column displays the exon or intron number for each
SPRED1 gene variant. Mutation Type describes the biological event
leading to the change in the DNA (relative to the reference sequence).
Common types of variants include small deletions and insertions/
duplications, missense, nonsense, splice-site, silent, and recently, large
deletions (those equal to or larger than a single exon) that have been
reported (Spencer et al. 2011). Large duplications have not been
reported in individuals with Legius syndrome. SPRED1 gene variant
mutation types are graphically summarized in Figure 2.
SPRED1 genotype: T h eN u c l e o t i d eC h a n g ec o l u m nd i s p l a y st h e
corresponding HGVS nomenclature (Den Dunnen and Antonarakis
2000). For cDNA numbering in the Nucleotide Change column of the
SPRED1 database, the ﬁrst cDNA nucleotide (c.1) is the “A” of the
ATG initiation (start) codon.
SPRED1 protein change: For the Protein Change column, the single
amino acid changes are listed in the database display. Where splice-
site variants occur, only the genotype is listed, with the protein change
indicated with a question mark.
Classiﬁcation of pathogenicity: In the Classiﬁcation column, deﬁni-
tions for pathogenicity are Pathogenic, Suspected Pathogenic, Benign,
Suspected Benign, or Uncertain. As is common practice, loss of func-
tion (LOF) mutations are assumed pathogenic, and the author’sc l a s -
siﬁcation for each variant was used.
Legius syndrome phenotype: The phenotype associated with each
variant is listed by author if the variant was reported more than once.
References and comments: The ﬁnal two columns of the database
feature links to literature resources and genotype/phenotype ﬁndings
of each individual variant. As displayed in Figure 1D, moving the
cursor over the comments icon highlights a key feature and unique
part of this online resource. Comments for each SPRED1 variant often
contain additional information or evidence to support the classiﬁca-
tion designation and whether the patient meets NIH diagnostic crite-
ria for a clinical diagnosis of NF1. Importantly, clinical details, such as
age or other conditions, may be included. Sensitive and private patient
information is never listed.
Database contents
Currently, the database displays information and classiﬁcation of 78
SPRED1 gene variants. However, this number is actively increasing as
additional variants are described in the scientiﬁc literature and dis-
covered in routine clinical testing and research laboratories. Patho-
genic mutations detected during routine clinical testing of patient
samples at ARUP Laboratories or those submitted by other laborato-
ries will also be added to the database. As mentioned above, for
variants included from the scientiﬁc literature, the database provides
a linked reference to the PubMed abstract for each variant. Because
the classiﬁcation of each variant is directly based on evidence from the
scientiﬁc literature, the link to PubMed is a very useful feature of this
database. However, in cases where a variant has not yet been reported
in the literature, the database provides the clinical and/or experimen-
tal, functional data suggestive of its classiﬁcation. Laboratories and
database users may also contact curators via e-mail or phone regard-
ing database entries, additional references, or clariﬁcation of informa-
tion posted on the site at any time.
Figure 2 summarizes the content of the SPRED1 database by var-
iant classiﬁcation and mutation types. Analysis of the different types
of mutations currently contained in the database are provided, in-
cluding deletion (16), large deletion (3), insertion/deletion (1), dupli-
cation (6), insertion (4), missense (23), nonsense (16), silent (4),
intronic (4) and splice site effect (1).
Clinical signiﬁcance of the database
Clinical and research laboratories that offer full gene analysis often
encounter rare variants and must rely on the published literature or
online resources to make informed decisions about the classiﬁcation
of the variant when reporting their ﬁndings. We developed this
database to facilitate this decision-making process and assist those
who interpret results and care for patients. A key feature of this
database is the ease of access with which it provides pertinent gene
variant information and the associated genotype-phenotype observa-
tions. In addition, the database is curated by individuals with expertise
in molecular genetics and Legius syndrome, ensuring that all of the
information contained in the archive is up to date and of sufﬁcient
scientiﬁc rigor. Finally, as this database is a publicly available resource,
with no login or membership requirement, it serves as an ideal
centralized resource to all laboratories offering SPRED1 gene analysis,
as well as to genetic counselors or physicians treating patients.
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Figure 2 Dynamic graphical summary of (A) variant classiﬁcation and
(B) types of mutations found in the SPRED1 database.
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